A concentrated form of prothrombin complex appears to rapidly and permanently reverse the effects of the novel anticoagulant rivaroxaban, a factor Xa inhibitor. But according to results of a small ...

Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients 1–4 EU approval follows recent U.S. FDA approval ...

RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy Both Pradaxa® doses tested in RE-DUAL PCI™ have ...

Combination NOAC therapy. The data suggest possible variability across NOACs regarding gastrointestinal bleeding risk, with an increased risk associated with rivaroxaban and dabigatran. Non–vitamin K ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...

Use of the novel oral anticoagulants dabigatran and rivaroxaban is contraindicated in patients undergoing dialysis because the drugs can bioaccumulate and cause increased bleeding. Dabigatran and ...

Across the RE‑COVER trials, 9 patients (0.4%) in the dabigatran arms and 5 (0.2%) in the warfarin arms had an acute coronary syndrome event. Of these, 8 patients (0.3%) in the dabigatran arms and 4 (0 ...

RIDGEFIELD, Conn., Nov. 10, 2017 /PRNewswire/ -- Boehringer Ingelheim today announced that important sub-analyses from three major trials in anticoagulation care will be presented at the American ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with anticoagulants Pradaxa and Xarelto did not experience severe hemorrhagic complications ...

PRADAXA (dabigatran etexilate) 75mg, 150mg capsules by Boehringer Ingelheim This marks the fourth FDA approval for the anticoagulant. The Food and Drug Administration (FDA) has approved Pradaxa ...